ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links0 made here, not in the record7 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06340568A Clinical Study of theAnti-cancer Effects of anInvestigational Therapy orChemotherapy in PatientsWith Recurring UterineCancerBioNTech SEPhase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 16 · ClinicalTrials.gov record · Version of 2026-10-16Nov 10 · ClinicalTrials.gov record · Version of 2026-11-10Version of 2026-11-10CONDITIONSEndometrial NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSTrastuzumab pamirtecanEntry “BNT323/DB-1303”, read by our n…›Nov 18 · Rule based · TestedTestedDoxorubicinIntervention entry›Nov 18 · Rule based · ComparatorComparatorPaclitaxelIntervention entry›Nov 18 · Rule based · ComparatorComparatorDocetaxelIntervention entry›Nov 18 · Rule based · ComparatorComparatorTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Trastuzumab

From the registry record1 judgment on this link
Role in the study, from the registry to what was judged
RegistryIntervention entrythe record gives no role
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Oct 16The record itselfClinicalTrials.gov recordVersion of 2026-10-16Record change
Nov 2TrastuzumabClaude Opus 5.5Not givenCurrent
Nov 10The record itselfClinicalTrials.gov recordVersion of 2026-11-10Record change
Nov 14Endometrial NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 18Trastuzumab pamirtecanRule based · role ruleTestedCurrent
Nov 18DoxorubicinRule based · role ruleComparatorCurrent
Nov 18PaclitaxelRule based · role ruleComparatorCurrent
Nov 18DocetaxelRule based · role ruleComparatorCurrent
As of nowEndometrial NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.